Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery

Hepato-Gastroenterology

Volumn 47, Issue 33, 2000, Pages 644-649

  Todoroki, Takeshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bile duct carcinoma; Chemotherapy; Cholangiocarcinoma; Hepatic arterial infusion chemotherapy; Intraductal infusion chemotherapy; Systemic chemotherapy

Indexed keywords

CISPLATIN; DOXIFLURIDINE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; METHOTREXATE; MITOMYCIN C; OCTREOTIDE; RIFAMPICIN; TAMOXIFEN; URACIL;

ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SURGERY; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL;

EID: 0034097860     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. 1 Bukowski RM, Leichman LP, Rivkin SE: Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group study. Eur J Cancer Clin Oncol 1983; 19:721-723.
2. 2 Falkson G, Macintyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54:965-969.
3. 3 Ravry MJ, Omura GA, Bartolucci AA, et al: Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986; 70:311-312.
4. 4 Taal BG, Audisio RA, Bleiberg H, et al: Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study. Ann Oncol 1993; 4:607-609.
5. 5 Okada S, Ishii H, Nose H, et al: A Phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51:515-517.
6. 6 Jones DVJ, Lozani R, Hoque A, et al: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14:2306-2310.
7. 7 Davis HL, Jr, Ramirez G, Ansfield FL: Adenocarcinomas of stomach, pancreas, liver and biliary tracts. Cancer 1974; 33:193-197.
8. 8 Takada T, Uchiyama K: Chemotherapy for unresectable biliary cancer. Kan Tan Sui 1992; 25:695-699. (In Japanese)
9. 9 Sali A, McQuillan T, Read A, et al: Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases. J Cancer Res Clin Oncol 1991; 117:503-504.
10. 10 Mezger J, Sauerbruch T, Ko Y, et al: Phase II trial of gemcitabine (GEM) in biliary tract cancers (BTC). Proc ASCO 1997; 16:297a.
11. 11 Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41:73-81.
12. 12 den Hartigh J, McVie JG, van Oort WJ, et al: Pharmacokinetics of mitomycin C in humans. Cancer Res 1983; 43:5017-5021.
13. 13 Sulkowski U, Dinse P, Hans U, et al: Regression of a distal bile duct carcinoma after treatment with Octreotide for 6 months. Digestion 1997; 58:407-409.
14. 14 Tan CK, Podila PV, Taylor JE, et al: Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995; 108:1908-1916.
15. 15 Harvey JH, Smith FP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2:1245-1248.
16. 16 Kajanti M, Pyrhönen S: Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. Am J Clin Oncol 1994; 17:223-226.
17. 17 Patt YZ, Jones DVJ, Hoque A, et al: Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14:2311-2315.
18. 18 Sanz-Altamira PM, Ferrante K, Jenkins RL, et al: A phase ii study of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82:2321-2325.
19. 19 Ekström K, Hoffman K, TL, et al: Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study. Oncol Rep 1998; 5:931-934.
20. 20 Adolphson CC, Carpenter JTJ: Response to doxorubicin and mitomycin in cholangiocarcinoma: a case report. Cancer Treat Rep 1982; 66:209-210.
21. 21 Riggs CEJ, Benjamin RS, Serpick AA, et al: Biliary disposition of Adriamycin. Clin Pharmacol Ther 1977; 22:234-241.
22. 22 Cadman E, Heimer R, Benz C: The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210. J Biol Chem 1981; 256:1695-1704.
23. 23 Houghton JA, Maroda SJJ, Phillips JO, et al: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 1981; 41:144-149.
24. 24 Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83:8923-8925.
25. 25 Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
26. 26 Yee LK, Allegra CJ, Steinberg SM, et al: Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a. J Natl Cancer Inst 1992; 84:1820-1825.
27. 27 Cambareri RJ, Smith FP, Kales A, et al: FAM, 5-fluorouracil (F), Adriamycin (A), and mitomycin-C (M), in cholangiocarcinoma. Proc AACR ASCO 1980; 21:419. (Abstract)
28. 28 Uchiyama K, Takada T, Yasuda H, et al: A case of intrahepatic bile duct cancer responding to 5-fluorouracil, Adriamycin and mitomycin-C chemotherapy. Jpn J Cancer Chemother 1988; 15:1987-1990. (In Japanese)
29. 29 Issacoff WH, Botnick L, Tompkins R, et al: Treatment of patients with advanced tumors of the bile ducts with calcium leucovorin (LV), mitomycin-C (MITO-C.) and dipyridamole (D). Proc ASCO 1993; 12:225.
30. 30 Ellis PA, Hill HA, O'Brien MER, et al: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumour. Eur J Cancer 1995; 31A:1594-1598.
31. 31 Colleoni M, Di Bartolomeo M, Di Leo A, et al: Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur J Cancer 1995; 31A:2427-2428. (Letters)
32. 32 Sakata Y, Fukushi G, Tsushima K, et al: MQF-FT and MQF-UFT in gallbladder and bile duct cancer. Jpn J Cancer Chemother 1988; 15:2731-2735. (In Japanese)
33. 33 Shibata T, Sato T, Kondo H, et al: Two cases of obstructive jaundice due to extrahepatic carcinoma of bile duct with marked response to daily oral administration of etoposide. Jpn J Cancer Chemother 1990; 17:2429-2432. (In Japanese)
34. 34 Kouda K, Kure S, Terada S, et al: Combination therapy with UFT and Adriamycin for advanced gastrointestinal malignancies. Gann no Rinshou 1987; 33:1329-1335. (In Japanese)
35. 35 Northover JM, Terblanche J: A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 1979; 66:379-84.
36. 36 Sullivan RD, Zurek WZ: Chemotherapy for liver cancer by protracted ambulatory infusion. JAMA 1965; 194:481-486.
37. 37 Massey WH, Fletcher WS, Judkins MP, et al: Hepatic artery infusion for metastatic malignancy using percutaneously placed catheter. Am J Surg 1971; 121:160-164.
38. 38 Warren KW, Mountain JC, Jones WL: Malignant tumours of the bile-ducts. Br J Surg 1972; 59:501-505.
39. 39 Garnick MB, Einsminger WD, Israel M: A clinical-pharmacological evaluation of hepatic arterial infusion of Adriamycin. Cancer Res 1979; 39:4105-4110.
40. 40 Smith WG, Bukowski RM, Hewlett JS, et al: Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 1984; 54:1513-1516.
41. 41 McAleer JJA, Dickey W, Clarke R, et al: Regional lipiodolized chemotherapy for cholangiocarcinoma associated with oral contraceptives. Postgrad Med J 1987; 63:583-584.
42. 42 Seeger J, Woodcock TM, Blumenreich MS, et al: Hepatic perfusion with FUDR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver. Cancer Invest 1989; 7:1-6.
43. 43 Uehara S, Hirano F, Sakaki N, et al: A case of cholangiocarcinoma with marked reduction of tumour after oral administration of UFT. Jpn J Cancer Chemother 1989; 16:2944-2948. (In Japanese)
44. 44 Tsuji Y, Nishimura A, Katsuki Y, et al: Evaluation of long surviving cases treated with intra-arterial cancer chemotherapy using implantable reservoirs. Jpn J Cancer Chemother 1989; 5:439-443. (In Japanese)
45. 45 Tsushima K, Sakata Y, Shiratori Y, et al: Cases of advanced cholangiocarcinoma showing partial response by the combination chemotherapy including protracted continuous infusion of 5-FU combined with intravenous administration of low-dose leucovolin and intra-arterial administration of MMC and CQ. Jpn J Cancer Chemother 1991; 18:2603-2605. (In Japanese)
46. 46 Tsuji Y, Imai M, Katsuki Y, et al: A case of liver metastasis from bile duct cancer effectively treated with hepatic artery infusion chemotherapy. Jpn J Cancer Chemother 1994; 21:2194-2197. (In Japanese)
47. 47 Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459-465.
48. 48 Soeno T, Sasahara M, Shoji S, et al: Trial of anti-cancer drug administration using PTC-D tube for inoperable patients with bile duct cancer. Jpn J Cancer Chemother 1978; 5:439-443. (In Japanese)
49. 49 Maeda M, Izumi A, Kanayama H, et al: Intraductal chemotherapy for biliary tract malignancy. Gann no Rinshou 1981; 27:330-336. (In Japanese)
50. 50 Mizuno I, Tanada F, Iwai A, et al: Intrabiliary tract administration of Adriamycin in bile duct cancer. Jpn J Cancer Chemother 1982; 9:681-687. (In Japanese)
51. 51 Suyama M, Ariyama Y, Ogawa K, et al: Conservative therapy of the biliary tract carcinoma. Kann Tann Sui 1987; 14:409-412. (In Japanese)
52. 52 Okazaki K, Sakamoto Y, Morita M, et al: A trial of intraluminal CDDP therapy for cancer of the biliary tract. Tann to Sui 1987; 8:489-497. (In Japanese)
53. 53 Yamashina T, Maruyam H, Murakami T, et al: A long surviving case of carcinoma of the common hepatic duct treated by chemotherapy with CDDP in the percutaneous external biliary tube and endoprosthesis 1996; 93:927-931. Nippon Shokakibyo Gakkai Zasshi. (In Japanese).
54. 54 Schmeck HJ, Bartels E, Viets CH, et al: Intraduktale chemotherapie eines gallengangskarzinoms. Klin Wochenschr 1986; 64:713-716. (In German)